PROBLEM TO BE SOLVED: To provide a useful pancreatic cancer therapeutic agent to pancreatic cancer, particularly progressive pancreatic cancer.SOLUTION: There is provided a pancreatic cancer therapeutic agent in which gemcitabine as an active ingredient, cimetidine as an active ingredient and sodium valproate as an active ingredient are combined. It is preferable that the pancreatic cancer therapeutic agent is administrated in the following modes: (1) gemcitabine: 100 to 1500 mg of gemcitabine is continuously administered for 3 weeks per a week and withdrawn at fourth week or continuously administered for 2 weeks per a week and withdrawn at third week (2) cimetidine: 100 to 3200 mg of cimetidine is administered everyday at two times per a day, administered at once per several days or administered at several times in every two weeks (3) sodium valproate: 100 to 3000 mg of sodium valproate is administered everyday at two times per a day, administered at once per several days or administered at several times in every two weeks. It is preferable that administration of the pancreatic cancer therapeutic agent is additionally combined with an administration mode in which 5 to 60 mg of olanzapine as an active ingredient is administered everyday, administered at once per several days or administered at several times in every two weeks.COPYRIGHT: (C)2015,JPO&INPIT【課題】膵臓癌、特に進行性膵臓癌に対して有用な膵臓癌治療剤を提供する。【解決手段】有効成分であるゲムシタビン、有効成分であるシメチジン及び有効成分であるバルプロ酸ナトリウムを組み合わせた膵臓癌治療剤。該膵臓癌治療剤は、(1)ゲムシタビン:100~1500mgの週1回投与を3週連続し、4週目は休薬する又は、週1回投与を2週連続し、3週目は休薬する、(2)シメチジン:100~3200mgを1日に2回に分けて連日投与、数日に1回投与又は隔週に数回投与する、(3)バルプロ酸ナトリウム:100~3000mgを1日に2回に分けて連日投与、数日に1回投与又は隔週に数回投与する、投与形態であることが好ましい。該膵臓癌治療剤は、さらに有効成分であるオランザピンを5~60mg連日投与、数日に1回投与又は隔週に数回投与する投与形態を組み合わせることが好ましい。【選択図】なし
